Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NK 001 - EMERCell

Drug Profile

NK 001 - EMERCell

Alternative Names: NK-001 - EMERCell

Latest Information Update: 26 Sep 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator EMERCell
  • Developer EMERCell; Onward Therapeutics
  • Class Antineoplastics; Immunotherapies; Natural killer cell therapies
  • Mechanism of Action Natural killer cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Acute myeloid leukaemia; Lymphoma

Most Recent Events

  • 26 Sep 2022 Emercell plans a clinical trial for lymphoma (Second-line therapy or greater) in France in 2023
  • 23 Jun 2021 EMERCell plans preclinical studies in solid tumour (Combination therapy) (Parenteral) (EMERCell website, June 2021)
  • 14 Jun 2021 Preclinical trials in Lymphoma (Combination therapy) in France (Parenteral) prior to June 2021 (EMERcell website, June 2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top